Gu Xuehan personally went to Xinran Biotech to communicate with the numerous dismissed employees. This was entirely unexpected. Generally, in such class-action lawsuits, she would delegate the initial investigation and evidence collection to Qi Xi or Gu Yan. Unfortunately, her two capable team assistants had recently gotten married and applied for a honeymoon leave. This meant that for nearly half a month, Gu Xuehan would have to face the predicament of having no one to assist her, forcing her to handle many matters personally.
Xinran Biotech was a biopharmaceutical company, a subsidiary of the Tan family's business empire. After years of burning through investment money, three targeted drugs have been approved this year and can be put into production and enter the market. Although it has not yet achieved full profitability, it has already secured $100 million in Series E financing. After this round of financing, the market is expected to value the company at $1 billion.
Logically, with Xinran Biotech's strong development momentum and the Tan family's seemingly endless supply of money, the company should have comprehensive legal and lawyer consultants to ensure legal compliance. They should be avoiding disputes in commercial contracts, let alone such basic labor contract disputes. Especially after the interviews, Gu Xuehan discovered that these dismissals were indeed very suspicious.